Pancreas and pancreatitis: Exocrine pancreatic insufficiency.
chymotrypsin
coefficient of fat absorption
exocrine pancreatic insufficiency
fecal elastase
Journal
Pediatric pulmonology
ISSN: 1099-0496
Titre abrégé: Pediatr Pulmonol
Pays: United States
ID NLM: 8510590
Informations de publication
Date de publication:
Sep 2024
Sep 2024
Historique:
revised:
23
03
2024
received:
23
08
2023
accepted:
04
04
2024
medline:
6
8
2024
pubmed:
6
8
2024
entrez:
6
8
2024
Statut:
ppublish
Résumé
Exocrine pancreatic insufficiency (EPI) is highly prevalent among individuals with cystic fibrosis (CF). Individuals diagnosed with EPI are often labeled as having "pancreas insufficient cystic fibrosis (PI-CF)" while those with normal exocrine function are labeled as "pancreas sufficient CF (PS-CF)." This diagnosis of EPI relies on clinical and laboratory features and management involves consumption of pancreas enzyme replacement therapy. In this review, we discuss the nuances of diagnosis and management of EPI in CF. We also present emerging evidence on the effects of CFTR modulating agents on the management of EPI, and speculate that these medications may lead to greater heterogeneity in management of EPI in CF moving forward.
Substances chimiques
Cystic Fibrosis Transmembrane Conductance Regulator
126880-72-6
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
S44-S52Subventions
Organisme : Cystic Fibrosis Foundation
Organisme : Developing Innovative Gastroenterology Specialty Training Program
Informations de copyright
© 2024 The Authors. Pediatric Pulmonology published by Wiley Periodicals LLC.
Références
Jeffrey FW. Cystic fibrosis of the pancreas. Can Med Assoc J. 1941;45:224‐229.
Andersen DH. Cystic fibrosis of the pancreas and its relation to celiac disease: a clinical and pathologic studY. Am J Dis Child. 1938;56:344‐399.
Dickey L. The pulmonary aspects of cystic fibrosis of the pancreas. Cal West Med. 1942;57:41‐42.
Corey M, McLaughlin FJ, Williams M, Levison H. A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. J Clin Epidemiol. 1988;41:583‐591.
Marino CR, Matovcik LM, Gorelick FS, Cohn JA. Localization of the cystic fibrosis transmembrane conductance regulator in pancreas. J Clin Invest. 1991;88:712‐716.
Pallagi P, Hegyi P, Rakonczay Jr. Z, et al. The physiology and pathophysiology of pancreatic ductal secretion: the background for clinicians. Pancreas. 2015;44:1211‐1233.
Ooi CY, Dorfman R, Cipolli M, et al. Type of CFTR mutation determines risk of pancreatitis in patients with cystic fibrosis. Gastroenterology. 2011;140:153‐161.
Terlizzi V, Tosco A, Tomaiuolo R, et al. Prediction of acute pancreatitis risk based on PIP score in children with cystic fibrosis. Journal of Cystic Fibrosis. 2014;13:579‐584.
Borowitz D, Baker SS, Duffy L, et al. Use of fecal elastase‐1 to classify pancreatic status in patients with cystic fibrosis. J Pediatr. 2004;145:322‐326.
O'Sullivan BP, Baker D, Leung KG, Reed G, Baker SS, Borowitz D. Evolution of pancreatic function during the first year in infants with cystic fibrosis. J Pediatr. 2013;162:808‐812.
Ramsey ML, Li SS, Lara LF, et al. Cystic fibrosis transmembrane conductance regulator modulators and the exocrine pancreas: a scoping review. J Cyst Fibros. 2023;22(2):193‐200.
Fortner CN, Seguin JM, Kay DM. Normal pancreatic function and false‐negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy. J Cyst Fibros. 2021;20:835‐836.
Gould MJ, Smith H, Rayment JH, Machida H, Gonska T, Galante GJ. CFTR modulators increase risk of acute pancreatitis in pancreatic insufficient patients with cystic fibrosis. J Cyst Fibros. 2022;21(4):600‐602.
Lindkvist B. Diagnosis and treatment of pancreatic exocrine insufficiency. World J Gastroenterol. 2013;19(42):7258‐7266.
Khan A, Vege SS, Dudeja V, Chari ST. Staging exocrine pancreatic dysfunction. Pancreatology. 2022;22:168‐172.
Taylor CJ, Chen K, Horvath K, et al. ESPGHAN and NASPGHAN report on the assessment of exocrine pancreatic function and pancreatitis in children. J Pediatr Gastroenterol Nutr. 2015;61:144‐153.
Ammoury RF, Croffie JM. Malabsorptive disorders of childhood. Pediatr Rev. 2010;31(10):407‐416.
DiMagno EP, Go VLW, Summerskill WHJ. Relations between pancreatic enzyme outputs and malabsorption in severe pancreatic insufficiency. N Engl J Med. 1973;288:813‐815.
Lindkvist B, Phillips ME, Domínguez‐Muñoz JE. Clinical, anthropometric and laboratory nutritional markers of pancreatic exocrine insufficiency: prevalence and diagnostic use. Pancreatology. 2015;15:589‐597.
Wouthuyzen‐Bakker M, Bodewes FAJA, Verkade HJ. Persistent fat malabsorption in cystic fibrosis; lessons from patients and mice. J Cyst Fibros. 2011;10:150‐158.
Fieker A, Philpott J, Armand M. Enzyme replacement therapy for pancreatic insufficiency: present and future. Clin Exp Gastroenterol. 2011;4:55‐73.
Rana M, Wong‐See D, Katz T, et al. Fat‐soluble vitamin deficiency in children and adolescents with cystic fibrosis. J Clin Pathol. 2014;67:605‐608.
Feranchak AP, Sontag MK, Wagener JS, Hammond KB, Accurso FJ, Sokol RJ. Prospective, long‐term study of fat‐soluble vitamin status in children with cystic fibrosis identified by newborn screen. J Pediatr. 1999;135:601‐610.
Lancellotti L, D'Orazio C, Mastella G, Mazzi G, Lippi U. Deficiency of vitamins E and A in cystic fibrosis is independent of pancreatic function and current enzyme and vitamin supplementation. Eur J Pediatr. 1996;155:281‐285.
Lagrange‐Puget M, Durieu I, Ecochard R, et al. Longitudinal study of oxidative status in 312 cystic fibrosis patients in stable state and during bronchial exacerbation. Pediatr Pulmonol. 2004;38:43‐49.
Rashid M, Durie P, Andrew M, et al. Prevalence of vitamin K deficiency in cystic fibrosis. Am J Clin Nutr. 1999;70:378‐382.
Dreiling DA, Hollander F. Studies in pancreatic function; preliminary series of clinical studies with the secretin test. Gastroenterology. 1948;11:714‐729.
Carriere F, Barrowman JA, Verger R, René L. Secretion and contribution to lipolysis of gastric and pancreatic lipases during a test meal in humans. Gastroenterology. 1993;105:876‐888.
Lieb II, JG, Draganov PV. Pancreatic function testing: here to stay for the 21st century. World J Gastroenterol. 2008;14:3149‐3158.
Patel N, Sellers ZM, Grover A, et al. Endoscopic pancreatic function testing (ePFT) in children: a position paper from the NASPGHAN pancreas committee. J Pediatr Gastroenterol Nutr. 2021;72:144‐150.
Conwell DL, Zuccaro G, Vargo JJ, et al. An endoscopic pancreatic function test with synthetic porcine secretin for the evaluation of chronic abdominal pain and suspected chronic pancreatitis. Gastrointest Endosc. 2003;57(1):37‐40.
Del Rosario MAF, Fitzgerald JF, Gupta SK, Croffie JM. Direct measurement of pancreatic enzymes after stimulation with secretin versus secretin plus cholecystokinin. J Pediatr Gastroenterol Nutr. 2000;31(1):28‐32.
Engjom T, Erchinger F, Lærum BN, et al. Diagnostic accuracy of a short endoscopic secretin test in patients with cystic fibrosis. Pancreas. 2015;44(8):1266‐1272.
Stevens T, Conwell DL, Zuccaro G, Lewis SA, Love TE. The efficiency of endoscopic pancreatic function testing is optimized using duodenal aspirates at 30 and 45 minutes after intravenous secretin. Am J Gastroenterol. 2007;102:297‐301.
Gullo L, Priori P, Costa PL, et al. Effects of morphine on human pancreatic secretion: studies on pure pancreatic juice. Gut. 1982;23(9):739‐743.
Saunders JH, Masoero G, Wormsley KG. Effect of diazepam and hyoscine butylbromide on response to secretin and cholecystokininpancreozymin in man. Gut. 1976;17:351‐353.
Daftary A, Acton J, Heubi J, Amin R. Fecal elastase‐1: utility in pancreatic function in cystic fibrosis. J Cyst Fibros. 2006;5:71‐76.
Domínguez‐Muñoz JE, D. Hardt P, Lerch MM, Löhr MJ. Potential for screening for pancreatic exocrine insufficiency using the fecal elastase‐1 test. Dig Dis Sci. 2017;62:1119‐1130.
Loser C, Mollgaard A, Folsch UR. Faecal elastase 1: a novel, highly sensitive, and specific tubeless pancreatic function test. Gut. 1996;39(4):580‐586.
Walkowiak J, Cichy WK, He K‐H. Comparison of fecal elastase‐1 determination with the secretin‐cholecystokinin test in patients with cystic fibrosis. Scand J Gastroenterol. 1999;34(2):202‐207.
Soldan W, Henker J, Sprössig C. Sensitivity and specificity of quantitative determination of pancreatic elastase 1 in feces of children. J Pediatr Gastroenterol Nutr. 1997;24(1):53‐55.
Walkowiak J, Nousia‐Arvanitakis S, Cade A, et al. Fecal elastase‐1 cut‐off levels in the assessment of exocrine pancreatic function in cystic fibrosis. J Cyst Fibros. 2002;1:260‐264.
Nissler K, Von Katte I, Huebner A, et al. Pancreatic elastase 1 in feces of preterm and term infants. J Pediatr Gastroenterol Nutr. 2001;33:28‐31.
Walkowiak J, Herzig KH, Strzykala K, Przyslawski J, Krawczynski M. Fecal elastase‐1 is superior to fecal chymotrypsin in the assessment of pancreatic involvement in cystic fibrosis. Pediatrics. 2002;110(1 Pt 1):e7.
Cade A, Walters M, McGinley N, et al. Evaluation of fecal pancreatic elastase‐1 as a measure of pancreatic exocrine function in children with cystic fibrosis. Pediatr Pulmonol. 2000;29(3):172‐176.
Hamwi A, Veitl M, Maenner G, Vogelsang H, Szekeres T. Pancreatic elastase 1 in stool: variations within one stool passage and individual changes from day to day. Wien Klin Wochenschr. 2000;112(1):32‐35.
Walkowiak J, Herzig KH. Fecal elastase‐1 is decreased in villous atrophy regardless of the underlying disease. Eur J Clin Invest. 2001;31:425‐430.
Schappi MG. Faecal elastase‐1 concentration is a marker of duodenal enteropathy. Arch Dis Child. 2002;86:50‐53.
Morinville VD, Husain SZ, Bai H, et al. Definitions of pediatric pancreatitis and survey of present clinical practices. J Pediatr Gastroenterol Nutr. 2012;55(3):261‐265.
van de Kamer JH, Huinink HB, Weyers HA. Rapid method for the determination of fat in feces. J Biol Chem. 1949;177:347‐355.
Weijers HA, Drion EF, Kamer JHVD. Analysis and interpretation of the fat‐absorption coefficient. Acta Paediatr (Stockholm). 1960;49:615‐625.
Bashaw H, Brownell JN, Schall JI, Stallings VA. Measures of dietary fat and energy absorption in healthy adults. Pancreas. 2020;49(6):845‐854.
Fomon SJ, Ziegler EE, Thomas LN, Jensen RL, Filer LJ. Excretion of fat by normal full‐term infants fed various milks and formulas. Am J Clin Nutr. 1970;23(10):1299‐1313.
Borowitz D, Aronoff N, Cummings LC, Maqbool A, Mulberg AE. Coefficient of fat absorption to measure the efficacy of pancreatic enzyme replacement therapy in people with cystic fibrosis: gold standard or coal standard? Pancreas. 2022;51:310‐318.
Korostensky M, Martin SR, Swain M, et al. Elimination of 72‐hour quantitative fecal fat testing by restriction, laboratory consultation, and evaluation of specimen weight and fat globules. J Appl Lab Med. 2018;3(3):357‐365.
Borowitz D, Robinson KA, Rosenfeld M, et al. Cystic fibrosis foundation evidence‐based guidelines for management of infants with cystic fibrosis. J Pediatr. 2009;155(6 suppl):S73‐S93.
Carlyle BE, Borowitz DS, Glick PL. A review of pathophysiology and management of fetuses and neonates with meconium ileus for the pediatric surgeon. J Pediatr Surg. 2012;47(4):772‐781.
Jordan PH, Grossman MI. Effect of dosage schedule on the efficacy of substitution therapy in pancreatic insufficiency. Gastroenterology. 1959;36(4):447‐451.
Keller J. Human pancreatic exocrine response to nutrients in health and disease. Gut. 2005;54(suppl VI):1‐28.
Domínguez‐Muñoz J. Pancreatic enzyme replacement therapy for pancreatic exocrine insufficiency: when is it indicated, what is the goal and how to do it? Adv Med Sci. 2011;56(1):1‐5.
DiMagno EP, Malagelada JR, Go VLW, Moertel CG. Fate of orally ingested enzymes in pancreatic insufficiency. Comparison of two dosage schedules. N Engl J Med. 1977;296(23):1318‐1322.
Domínguez‐Muñoz JE, Iglesias‐García J, Iglesias‐Rey M, Figueiras A, Vilariño‐Insua M. Effect of the administration schedule on the therapeutic efficacy of oral pancreatic enzyme supplements in patients with exocrine pancreatic insufficiency: a randomized, three‐way crossover study. Aliment Pharmacol Ther. 2005;21:993‐1000.
Freswick PN, Reid EK, Mascarenhas MR. Pancreatic enzyme replacement therapy in cystic fibrosis. Nutrients. 2022;14(7):1341.
Costantini D, Padoan R, Curcio L, Giunta A. The management of enzymatic therapy in cystic fibrosis patients by an individualized approach. J Pediatr Gastroenterol Nutr. 1988;7(suppl 1):S36‐S39.
Saxby N, Painter C, Kench A, Crowder T, van der Haak N, et al. Nutrition guidelines for Cystic Fibrosis in Australia and New Zealand [Internet]. Syndey: Thoracic Society of Australia and New Zealand; 2017. Available from https://www.cfnz.org.nz/assets/Reports/103e2ea215/Nutrition-Guidlines-for-CF-in-Australia-and-NZ-2017.pdf
Borowitz DS, Grand RJ, Durie PR. Use of pancreatic enzyme supplements for patients with cystic fibrosis in the context of fibrosing colonopathy. J Pediatr. 1995;127:681‐684.
Borowitz D, Gelfond D, Maguiness K, Heubi JE, Ramsey B. Maximal daily dose of pancreatic enzyme replacement therapy in infants with cystic fibrosis: a reconsideration. J Cyst Fibros. 2013;12:784‐785.
FitzSimmons SC, Burkhart GA, Borowitz D, et al. High‐dose pancreatic‐enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. N Engl J Med. 1997;336(18):1283‐1289.
Schechter MS, Michel S, Liu S, et al. Relationship of initial pancreatic enzyme replacement therapy dose with weight gain in infants with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2018;67:520‐526.
Padula L, Brownwell J, Reid E, et al. Childrens Hospital of Philadelphia Clinical Pathway for Pancreatic Enzyme Replacement Therapy (PERT) in Children with or at Risk for Exocrine Pancreatic Insufficiency (EPI). 2019.
Turck D, Braegger CP, Colombo C, et al. ESPEN‐ESPGHAN‐ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis. Clin Nutr. 2016;35:557‐577.
Schwarzenberg S, Dorsey J Pancreatic Enzymes Clinical Care Guidelines: Executive Summary. 2021: [cited 2023 Aug 17] Available from Available online: https://www.cff.org/medical-professionals/pancreatic-enzymes-clinical-care-guidelines#pancreatic-enzymes-clinical-care-guidelines-executive-summary
Ramsey M, Hart P, Forsmark C Evaluation and management of exocrine pancreatic insufficiency: pearls and pitfalls. Curr Opin Gastroenterol. 2012.
Sinaasappel M, Stern M, Littlewood J, et al. Nutrition in patients with cystic fibrosis: a European consensus. J Cyst Fibros. 2002;1:51‐75.
Leonard A, Bailey J, Bruce A, et al. Nutritional considerations for a new era: a CF foundation position paper. J Cyst Fibros. 2023;S1569‐1993(23):00140‐00146.
Sutherland R, Katz T, Liu V, et al. Dietary intake of energy‐dense, nutrient‐poor and nutrient‐dense food sources in children with cystic fibrosis. J Cyst Fibros. 2018;17:804‐810.
Sheibani L, Shafi N, Watson D. P320 comparing faecal elastase, pancreatic enzyme doses, HbA1c and insulin doses in adult cystic fibrosis patients pre‐ and 6 months postcommencement of Kaftrio®. J Cyst Fibros. 2023;22(suppl ment 2):S162.
Zybert K, Postek M, Wozniacki L, et al. P302 faecal calprotectin and elastase concentrations in patients before and after treatment with CFTR modulators. J Cyst Fibros. 2023;22:S157.
McKinzie C, Kam C, Stephenson K, et al. Repeat fecal elastase testing in pediatric patients on cystic fibrosis transmembrane conductance regulator modulator therapy. J Cyst Fibros, 21:S1223.
Gelfond D, Heltshe S, Ma C, et al. Impact of CFTR modulation on intestinal pH, motility, and clinical outcomes in patients with cystic fibrosis and the G551D mutation. Clin Transl Gastroenterol. 2017;8(3):e81.
Hoffman L, Pope C, Hayden H, Rowe S, Salipante S, Nichols D. Changes in fecal fat and microbiota with 1 month of elexacator/tezacaftor/ivacaftor: initial findings from the promise study. Pediatr Pulmonol. 2020;55(S2):218.